Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia.

Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia. Abstract Text:

Pamela DeRosse,Colin A Hodgkinson,Todd Lencz,Katherine E Burdick,John M Kane,David Goldman,Anil K Malhotra,

BACKGROUND: Converging evidence has demonstrated an association between the Disrupted in Schizophrenia 1 (DISC1) gene and schizophrenia (SZ). Within the DISC1 gene, a single nucleotide polymorphism (SNP), Ser704Cys, has been associated with the structure and function of the hippocampus. Because positive symptoms in SZ have also been associated with hippocampal structure and function, we hypothesized that variation in a DISC1 haplotype containing Ser704Cys would be significantly associated with positive symptomatology in SZ. METHODS: We tested for an association between variation in a haplotype block within the DISC1 gene containing Ser704Cys and lifetime history of positive symptoms in 199 Caucasian patients with SZ. RESULTS: We detected significant associations between a DISC1 haplotype containing Ser704Cys and Ser704Cys genotype and lifetime severity of delusions in SZ. CONCLUSIONS: These data suggest that that the effect of DISC1 genetic variation might be associated with positive symptoms in patients with SZ.

Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia. Publishing Authors By Initials

P DeRosse,CA Hodgkinson,T Lencz,KE Burdick,JM Kane,D Goldman,AK Malhotra,

For similar amino acids, peptides, and proteins: amino acids: amino acids, neutral: serine research abstracts see: amino acids, peptides, and proteins: amino acids: amino acids, neutral: serine research

PUBMED ID PMID:

MEDLINE DATE:

Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Biological psychiatry

VOLUME: 61

Page Numbers: 1208-10

Journal Abbreviation:

ISSN: 0006-3223

DAY: 19

MONTH: 10

YEAR: 2006

Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 213264

Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia. Keywords Mesh Terms:

KEYWORDS: Serine

MESH TERMS: genetics

Chemical & Substance for Abstract: Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia. Information

Substance Name: Serine

Registry Number: 56-45-1

Grant and Affiliation Information for Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia.

AFFILIATION: Department of Psychiatry Research, The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, Glen Oaks, New York 11004, USA. pderosse@lij.edu

Country: United States

AGENCY: United States NIMH

GRANT: MH001760

ACRONYM: MH

MEDLINETA: Biol Psychiatry

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia Related Publications

• A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia.
• Anaesthetic considerations in a patient with wolff-Parkinson-white syndrome.
• Biosensor for total cholesterol estimation using N-(2-aminoethyl)-3-aminopropyltrimethoxysilane self-assembled monolayer.
• COMT genotype and manic symptoms in schizophrenia.
• COMT genotype increases risk for bipolar I disorder and influences neurocognitive performance.
• Central sleep apnea: Pathophysiology and treatment.
• Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia.
• Corneal astigmatism with upper eyelid gold weight implantation using the combined high pretarsal and levator fixation technique.
• Cytokine release following recruitment maneuvers.
• DTNBP1 genotype influences cognitive decline in schizophrenia.
• Deep orbital sub-q restylane (nonanimal stabilized hyaluronic Acid) for orbital volume enhancement in sighted and anophthalmic orbits.
• Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia.
• Emotion-based decision-making in healthy subjects: short-term effects of reducing dopamine levels.
• Food vacuole targeting and trafficking of falcipain-2, an important cysteine protease of human malaria parasite Plasmodium falciparum.
• Genioglossus premotoneurons and the negative pressure reflex in rats.
• Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics.
• Intense F-18 FDG uptake noted in a benign bone cyst.
• Loop around ear - a simple method for maintaining central venous line with ordinary venous cannula.
• Native manual tonsillectomy: A dangerous practice in Asir.
• Overexpression and purification of human calcitonin gene-related peptide-receptor component protein in Escherichia coli.
• Presumed fresh mutation hemophilia A presenting with subarachnoid hemorrhage in a newborn.
• Renal vein thrombosis: a case report.
• RluD, a highly conserved pseudouridine synthase, modifies 50S subunits more specifically and efficiently than free 23S rRNA.
• Scleral infiltration in orbitotemporal plexiform neurofibromatosis.
• The FEZ1 gene shows no association to schizophrenia in Caucasian or African American populations.
• The Golgi-associated protein GRASP is required for unconventional protein secretion during development.
• The future of pharmacotherapy for schizophrenia.
• The influence of aging on pharyngeal collapsibility during sleep.
• Upper airway myopathy is not important in the pathophysiology of obstructive sleep apnea.
• Use of computational modeling to predict responses to upper airway surgery in obstructive sleep apnea.